10/2017: GTRx Specialty Pharmacy Network has launched. This is not a PBM – GTRx impacts medical spend J code drugs, therapies and medications. Available on a case by case basis or write GTRx into your plan as your designated Specialty Pharmacy Network. Always careful to respect the patient/doctor relationship, we will work with payor and provider to help the plan minimize what can be plan bankrupting costs. For TPA’s, self-administered plans or fully insured plans we can do an analysis of your current spend and advise if our network would be a more cost effective option.
GTRx initial impacts for clients on Remicade, Spinraza, Optivo, Keytruda and many more.
Pompe Disease, MS, Cancer, Hepatitis C, Hemophilia, Cystic Fibrosis, Melanoma, Nivolumab, Yervoy, Solaris: some of the most expensive diseases and/or drug therapies in the world today. Many pharmacy cases referred to us are for genetic disorders where there is no cure, but these expensive drugs can offer the patient potentially a better quality of life.
GTSN is contracted nationally with Cancer Treatment Centers of America. Until we launched GTRx in October 2017 most cases were worked individually through Single Patient Agreements. The providers are large and small, single doctor offices or leading medical systems and various outpatient centers in all 50 states.
Through GTRx we can still work with the local providers that are in place to obtain more manageable savings for the health plan.
Our fees are a percentage of savings with many referring parties already having access to discounts for our services. There is never a charge for initial case review and if you already have a great deal we’ll be the first to tell you. Read some of our Specialty Pharmacy Success Stories.
We’d love to discuss our services and how we are helping clients of all sizes across the US with savings that are guaranteed.
Contact Hy Byrd to learn more about better medical spend pharmacy savings.
Hy F. Byrd
Vice President – Business Development